Palatin Technologies, Inc. — Form 10-Q Summary
Reporting period: Fiscal third quarter and nine months ended March 31, 2023; filed May 15, 2023. The request metadata says “2022 Q3,” but the filing itself covers fiscal 2023 Q3.
Business context
Palatin is a biopharmaceutical company that markets Vyleesi in the United States and develops receptor-targeted drug candidates. Its pipeline includes PL9643 for dry eye disease and PL8177 for ulcerative colitis. Vyleesi is also licensed to partners for China and Korea.
Financial performance and liquidity
| Metric | Q3 FY2023 | Q3 FY2022 | Nine months FY2023 | Nine months FY2022 |
|---|---|---|---|---|
| Net revenue | $1.20 million | $0.22 million | $3.09 million | $0.70 million |
| Gross profit / margin | $1.07 million / 89.2% | $0.17 million / 78.3% | $2.78 million / 89.8% | $0.32 million / 81.4% |
| Operating loss | $7.30 million | $7.82 million | $21.64 million | $23.49 million |
| Net loss | $7.15 million | $7.63 million | $16.83 million | $23.43 million |
| Operating cash used | — | — | $18.81 million | $22.20 million |
At March 31, 2023, cash and cash equivalents were $19.63 million, down from $29.94 million at June 30, 2022. Current assets were $24.24 million and current liabilities were $11.85 million. The company reported no conventional borrowings in the supplied filing text; liabilities include operating and finance lease obligations. Total liabilities were $16.02 million.
Material changes and notable items
- Net product revenue rose substantially year over year, attributed to higher sales volume and lower sales allowances as a percentage of gross sales.
- Nine-month R&D expense increased to $15.22 million from $13.89 million, reflecting increased spending on melanocortin receptor programs. Quarterly R&D expense declined modestly.
- Nine-month net loss included a $4.67 million income tax benefit from selling New Jersey net operating losses and R&D credits, and a $1.03 million gain from reducing a Lonza purchase commitment.
- The company raised $9.11 million net from a November 2022 common-stock and warrant offering. Common shares outstanding increased to 11.15 million from 9.27 million at June 30, 2022.
- After quarter-end, Palatin sold 374,772 shares through a new at-the-market (ATM) agreement for net proceeds of $876,121 through May 12, 2023. The ATM permits up to $50 million in aggregate sales, subject to market conditions and dilution.
Outlook, risks and contingencies
Management concluded that substantial doubt exists about the company’s ability to continue as a going concern for one year from issuance of the financial statements. It expects current cash, based on existing plans, to fund anticipated operating expenses through calendar year 2023, but says additional financing or expense reductions are needed to support future operations. Potential actions include equity or debt financing, reducing spending, curtailing programs, or pursuing a strategic transaction. No formal revenue or earnings guidance is provided.
Key risks include ongoing cash burn and dependence on financing; clinical, regulatory and commercialization uncertainty; Vyleesi sales and market acceptance; reliance on contract manufacturers and licensees; and foreign-exchange exposure on supply commitments. Contractual inventory purchase commitments were reported as $7.84 million in the commitments table, while MD&A describes aggregate commitments of $6.89 million; the filing text does not explain this difference. The company reported no current material legal proceedings. Management stated disclosure controls were effective and reported no material change in internal control over financial reporting.
Most important facts for investors to verify
- Cash runway assumptions and progress in securing financing beyond the expected calendar-year 2023 funding horizon.
- Vyleesi prescription, gross-sales and net-sales trends, and the basis for product allowances and commercial spending.
- Clinical milestones, costs and timing for PL9643, PL8177 and other development programs.
- The reconciliation of the $7.84 million contractual inventory commitment total with the $6.89 million amount cited in MD&A.
- Actual ATM issuance, proceeds and resulting dilution after May 12, 2023, as well as any further financing or spending changes.